Gilead Announces 24-Week Results from Phase II Study of Investigational HIV Integrase Inhibitor GS 9137
"Integrase inhibitors represent a promising new class in the field of HIV treatment, and I am encouraged by these Phase II data for once-daily GS 9137," said Dr. Zolopa. "As a clinician, I am frequently reminded of the importance of expanding simplified treatment options for people living with HIV, particularly among treatment-experienced patients who have developed resistance to many existing medications."
Integrase inhibitors are an investigational class of antiretrovirals that interfere with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells. Novel classes of HIV-fighting drugs are needed as patients live longer and exhaust currently available treatment options.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.